ES2928096T3 - Un proceso para la concentración de un polipéptido - Google Patents

Un proceso para la concentración de un polipéptido Download PDF

Info

Publication number: ES2928096T3
Authority: ES; Spain
Prior art keywords: composition; polypeptide; arylsulfatase; range; interest
Prior art date: 2006-04-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES13167428T

Other languages

English (en)

Spanish (es)

Inventor

Stefan Nilsson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-04

Filing date

2007-04-04

Publication date

2022-11-15

2007-04-04 Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd

2022-11-15 Application granted granted Critical

2022-11-15 Publication of ES2928096T3 publication Critical patent/ES2928096T3/es

Status Active legal-status Critical Current

2027-04-04 Anticipated expiration legal-status Critical

Links

238000000034 method Methods 0.000 title claims abstract description 72
230000008569 process Effects 0.000 title claims description 12
108090000765 processed proteins & peptides Proteins 0.000 title abstract description 155
102000004196 processed proteins & peptides Human genes 0.000 title abstract description 153
229920001184 polypeptide Polymers 0.000 title abstract description 150
239000000203 mixture Substances 0.000 claims abstract description 133
102100022146 Arylsulfatase A Human genes 0.000 claims description 67
108010036867 Cerebroside-Sulfatase Proteins 0.000 claims description 66
102000004190 Enzymes Human genes 0.000 claims description 63
108090000790 Enzymes Proteins 0.000 claims description 63
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 44
210000004027 cell Anatomy 0.000 claims description 39
108090000623 proteins and genes Proteins 0.000 claims description 35
102000004169 proteins and genes Human genes 0.000 claims description 31
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 28
229930195725 Mannitol Natural products 0.000 claims description 28
239000000594 mannitol Substances 0.000 claims description 28
235000010355 mannitol Nutrition 0.000 claims description 28
230000000694 effects Effects 0.000 claims description 24
239000004471 Glycine Substances 0.000 claims description 22
239000000872 buffer Substances 0.000 claims description 21
150000007523 nucleic acids Chemical group 0.000 claims description 19
150000001413 amino acids Chemical group 0.000 claims description 17
108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 16
101000901140 Homo sapiens Arylsulfatase A Proteins 0.000 claims description 15
238000005119 centrifugation Methods 0.000 claims description 15
238000001914 filtration Methods 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 12
201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 11
229910000397 disodium phosphate Inorganic materials 0.000 claims description 11
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
229930006000 Sucrose Natural products 0.000 claims description 10
239000005720 sucrose Substances 0.000 claims description 10
230000002255 enzymatic effect Effects 0.000 claims description 9
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 8
235000019800 disodium phosphate Nutrition 0.000 claims description 8
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
229920000053 polysorbate 80 Polymers 0.000 claims description 7
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
102100031491 Arylsulfatase B Human genes 0.000 claims description 5
108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 4
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
125000000539 amino acid group Chemical group 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 3
229960001153 serine Drugs 0.000 claims description 3
210000001236 prokaryotic cell Anatomy 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
238000010254 subcutaneous injection Methods 0.000 abstract description 11
239000007929 subcutaneous injection Substances 0.000 abstract description 11
241000124008 Mammalia Species 0.000 abstract description 9
201000010099 disease Diseases 0.000 abstract description 9
229940088598 enzyme Drugs 0.000 description 62
108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 55
102100034391 Porphobilinogen deaminase Human genes 0.000 description 54
239000000243 solution Substances 0.000 description 53
238000004108 freeze drying Methods 0.000 description 38
239000000047 product Substances 0.000 description 38
239000000546 pharmaceutical excipient Substances 0.000 description 36
108010012864 alpha-Mannosidase Proteins 0.000 description 31
235000018102 proteins Nutrition 0.000 description 30
239000012528 membrane Substances 0.000 description 29
102100023231 Lysosomal alpha-mannosidase Human genes 0.000 description 26
238000000137 annealing Methods 0.000 description 22
241000282414 Homo sapiens Species 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
125000003275 alpha amino acid group Chemical group 0.000 description 19
238000001035 drying Methods 0.000 description 17
238000009295 crossflow filtration Methods 0.000 description 15
150000001875 compounds Chemical class 0.000 description 14
102100028496 Galactocerebrosidase Human genes 0.000 description 13
NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 12
229940024606 amino acid Drugs 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 12
229910052588 hydroxylapatite Inorganic materials 0.000 description 12
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 11
238000001042 affinity chromatography Methods 0.000 description 10
238000004255 ion exchange chromatography Methods 0.000 description 10
230000008901 benefit Effects 0.000 description 9
239000003446 ligand Substances 0.000 description 9
238000003259 recombinant expression Methods 0.000 description 9
101000860395 Homo sapiens Galactocerebrosidase Proteins 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
238000007710 freezing Methods 0.000 description 8
230000008014 freezing Effects 0.000 description 8
239000011148 porous material Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
108060007951 sulfatase Proteins 0.000 description 8
206010036182 Porphyria acute Diseases 0.000 description 7
102000019199 alpha-Mannosidase Human genes 0.000 description 7
238000003556 assay Methods 0.000 description 7
239000012537 formulation buffer Substances 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
239000012465 retentate Substances 0.000 description 7
238000003860 storage Methods 0.000 description 7
102000009133 Arylsulfatases Human genes 0.000 description 6
QSHWIQZFGQKFMA-UHFFFAOYSA-N Porphobilinogen Natural products NCC=1NC=C(CCC(O)=O)C=1CC(O)=O QSHWIQZFGQKFMA-UHFFFAOYSA-N 0.000 description 6
239000008364 bulk solution Substances 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
230000007812 deficiency Effects 0.000 description 6
YPHQRHBJEUDWJW-UHFFFAOYSA-N porphobilinogen Chemical compound NCC1=NC=C(CCC(O)=O)[C]1CC(O)=O YPHQRHBJEUDWJW-UHFFFAOYSA-N 0.000 description 6
XMCCOOONGGUOLA-UHFFFAOYSA-N 2-hydroxy-5-nitrophenyl hydrogen sulfate Chemical compound OC1=CC=C([N+]([O-])=O)C=C1OS(O)(=O)=O XMCCOOONGGUOLA-UHFFFAOYSA-N 0.000 description 5
108010042681 Galactosylceramidase Proteins 0.000 description 5
102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 5
-1 Na-Citrate Chemical compound 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 5
230000003197 catalytic effect Effects 0.000 description 5
239000000919 ceramic Substances 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
238000000108 ultra-filtration Methods 0.000 description 5
XJNPNXSISMKQEX-UHFFFAOYSA-N 4-nitrocatechol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1O XJNPNXSISMKQEX-UHFFFAOYSA-N 0.000 description 4
208000005452 Acute intermittent porphyria Diseases 0.000 description 4
229920002271 DEAE-Sepharose Polymers 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
208000028226 Krabbe disease Diseases 0.000 description 4
108050006616 Mannose-6-phosphate receptors Proteins 0.000 description 4
239000004695 Polyether sulfone Substances 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 4
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000002132 lysosomal effect Effects 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
230000037361 pathway Effects 0.000 description 4
229920006393 polyether sulfone Polymers 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
WDFJYRZCZIUBPR-UHFFFAOYSA-N preuroporphyrinogen Chemical compound OC(=O)CC1=C(CO)NC(CC2=C(C(CCC(O)=O)=C(CC3=C(C(CCC(O)=O)=C(CC4=C(C(CCC(O)=O)=CN4)CC(O)=O)N3)CC(O)=O)N2)CC(O)=O)=C1CCC(O)=O WDFJYRZCZIUBPR-UHFFFAOYSA-N 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
238000011146 sterile filtration Methods 0.000 description 4
239000008223 sterile water Substances 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
238000010361 transduction Methods 0.000 description 4
230000026683 transduction Effects 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 3
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
101000979046 Homo sapiens Lysosomal alpha-mannosidase Proteins 0.000 description 3
208000015439 Lysosomal storage disease Diseases 0.000 description 3
208000027933 Mannosidase Deficiency disease Diseases 0.000 description 3
229920012266 Poly(ether sulfone) PES Polymers 0.000 description 3
241000097929 Porphyria Species 0.000 description 3
208000033141 Porphyria variegata Diseases 0.000 description 3
208000010642 Porphyrias Diseases 0.000 description 3
102100029028 Protoporphyrinogen oxidase Human genes 0.000 description 3
241000718541 Tetragastris balsamifera Species 0.000 description 3
201000011053 Variegate Porphyria Diseases 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
201000008333 alpha-mannosidosis Diseases 0.000 description 3
230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
229930183167 cerebroside Natural products 0.000 description 3
RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 3
239000013522 chelant Substances 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
238000011210 chromatographic step Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
238000007865 diluting Methods 0.000 description 3
239000012467 final product Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
150000003278 haem Chemical class 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229920001542 oligosaccharide Polymers 0.000 description 3
150000002482 oligosaccharides Chemical class 0.000 description 3
210000002826 placenta Anatomy 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
230000009145 protein modification Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000004627 regenerated cellulose Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
XMTCKNXTTXDPJX-UHFFFAOYSA-N 3-oxoalanine Chemical group O=CC(N)C(O)=O XMTCKNXTTXDPJX-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108010059892 Cellulase Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
101001067140 Homo sapiens Porphobilinogen deaminase Proteins 0.000 description 2
102000006386 Myelin Proteins Human genes 0.000 description 2
108010083674 Myelin Proteins Proteins 0.000 description 2
229920002274 Nalgene Polymers 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
102000005262 Sulfatase Human genes 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
230000009471 action Effects 0.000 description 2
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
229920005556 chlorobutyl Polymers 0.000 description 2
239000003593 chromogenic compound Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000000539 dimer Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
230000012202 endocytosis Effects 0.000 description 2
210000002472 endoplasmic reticulum Anatomy 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
208000016354 hearing loss disease Diseases 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000013580 millipore water Substances 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000005012 myelin Anatomy 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000008213 purified water Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000009450 sialylation Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000007787 solid Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
IYZXGLGVLYBKAI-UHFFFAOYSA-N 1-amino-4-[4-[[4-chloro-6-(4-sulfoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=C(S(O)(=O)=O)C=C1 IYZXGLGVLYBKAI-UHFFFAOYSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
MOTVYDVWODTRDF-UHFFFAOYSA-N 3-[7,12,17-tris(2-carboxyethyl)-3,8,13,18-tetrakis(carboxymethyl)-21,22-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CC(O)=O)C(=CC=3C(=C(CC(O)=O)C(=C4)N=3)CCC(O)=O)N2)CCC(O)=O)=C(CC(O)=O)C(CCC(O)=O)=C1C=C1C(CC(O)=O)=C(CCC(=O)O)C4=N1 MOTVYDVWODTRDF-UHFFFAOYSA-N 0.000 description 1
108010011619 6-Phytase Proteins 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
108010031396 Catechol oxidase Proteins 0.000 description 1
102000030523 Catechol oxidase Human genes 0.000 description 1
108010008885 Cellulose 1,4-beta-Cellobiosidase Proteins 0.000 description 1
108010022172 Chitinases Proteins 0.000 description 1
102000012286 Chitinases Human genes 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
102000005744 Glycoside Hydrolases Human genes 0.000 description 1
108010031186 Glycoside Hydrolases Proteins 0.000 description 1
208000000627 Hereditary Coproporphyria Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000008607 Integrin beta3 Human genes 0.000 description 1
108010020950 Integrin beta3 Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
108010029541 Laccase Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
102000004317 Lyases Human genes 0.000 description 1
108090000856 Lyases Proteins 0.000 description 1
102100024295 Maltase-glucoamylase Human genes 0.000 description 1
102000001696 Mannosidases Human genes 0.000 description 1
108010054377 Mannosidases Proteins 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
208000023109 Prominent forehead Diseases 0.000 description 1
JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
102000017852 Saposin Human genes 0.000 description 1
108050007079 Saposin Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108060008539 Transglutaminase Proteins 0.000 description 1
108020000963 Uroporphyrinogen-III synthase Proteins 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
241000195614 Volvox carteri Species 0.000 description 1
LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000013566 allergen Substances 0.000 description 1
WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical group OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
108010030291 alpha-Galactosidase Proteins 0.000 description 1
102000005840 alpha-Galactosidase Human genes 0.000 description 1
108010028144 alpha-Glucosidases Proteins 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
201000003554 argininosuccinic aciduria Diseases 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000025341 autosomal recessive disease Diseases 0.000 description 1
108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010047754 beta-Glucosidase Proteins 0.000 description 1
102000006995 beta-Glucosidase Human genes 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
239000012512 bulk drug substance Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
108010089934 carbohydrase Proteins 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940106157 cellulase Drugs 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
108010005400 cutinase Proteins 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
229940079919 digestives enzyme preparation Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
108010038658 exo-1,4-beta-D-xylosidase Proteins 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
206010019847 hepatosplenomegaly Diseases 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
239000001573 invertase Substances 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000036997 mental performance Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
210000003007 myelin sheath Anatomy 0.000 description 1
239000006225 natural substrate Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000001139 pH measurement Methods 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002351 pectolytic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000007030 peptide scission Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229940085127 phytase Drugs 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229940045627 porcine heparin Drugs 0.000 description 1
VCRBUDCZLSQJPZ-UHFFFAOYSA-N porphyrinogen Chemical compound C1C(N2)=CC=C2CC(N2)=CC=C2CC(N2)=CC=C2CC2=CC=C1N2 VCRBUDCZLSQJPZ-UHFFFAOYSA-N 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000001273 protein sequence alignment Methods 0.000 description 1
230000007398 protein translocation Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
239000012088 reference solution Substances 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000001890 transfection Methods 0.000 description 1
102000003601 transglutaminase Human genes 0.000 description 1
230000032258 transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000007306 turnover Effects 0.000 description 1
HUHWZXWWOFSFKF-UHFFFAOYSA-N uroporphyrinogen-III Chemical compound C1C(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(N2)=C(CC(O)=O)C(CCC(=O)O)=C2CC2=C(CCC(O)=O)C(CC(O)=O)=C1N2 HUHWZXWWOFSFKF-UHFFFAOYSA-N 0.000 description 1
102000003643 uroporphyrinogen-III synthase Human genes 0.000 description 1
239000004474 valine Substances 0.000 description 1
125000002987 valine group Chemical class [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1
150000008147 α-D-mannosides Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06001—Arylsulfatase (3.1.6.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01024—Alpha-mannosidase (3.2.1.24)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01046—Galactosylceramidase (3.2.1.46)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Water Supply & Treatment (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Diabetes (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

ES13167428T 2006-04-04 2007-04-04 Un proceso para la concentración de un polipéptido Active ES2928096T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200600488		2006-04-04
DKPA200600922		2006-07-05

Publications (1)

Publication Number	Publication Date
ES2928096T3 true ES2928096T3 (es)	2022-11-15

Family

ID=38472949

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
ES13167428T Active ES2928096T3 (es)	2006-04-04	2007-04-04	Un proceso para la concentración de un polipéptido
ES13167427T Active ES2713488T3 (es)	2006-04-04	2007-04-04	Un proceso para la concentración de un polipéptido
ES08166902T Active ES2744499T3 (es)	2006-04-04	2007-04-04	Un proceso para la concentración de un polipéptido

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
ES13167427T Active ES2713488T3 (es)	2006-04-04	2007-04-04	Un proceso para la concentración de un polipéptido
ES08166902T Active ES2744499T3 (es)	2006-04-04	2007-04-04	Un proceso para la concentración de un polipéptido

Country Status (20)

Country	Link
US (6)	US20090246187A1 (pt)
EP (4)	EP2100898B1 (pt)
JP (6)	JP2009532394A (pt)
KR (3)	KR20150103339A (pt)
CN (1)	CN105233276A (pt)
AU (2)	AU2007234195B2 (pt)
BR (1)	BRPI0709737A2 (pt)
CA (3)	CA2632528C (pt)
DK (1)	DK2628746T3 (pt)
ES (3)	ES2928096T3 (pt)
HU (1)	HUE042402T2 (pt)
IL (4)	IL194267A (pt)
MX (1)	MX2008012748A (pt)
NO (3)	NO347673B1 (pt)
NZ (7)	NZ623123A (pt)
PL (3)	PL2628746T3 (pt)
PT (1)	PT2628746T (pt)
SI (1)	SI2628746T1 (pt)
WO (1)	WO2007112757A2 (pt)
ZA (2)	ZA200805346B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ576986A (en)	2004-01-30	2010-12-24	Shire Pharmaceuticals Ireland Ltd	Production and purification of recombinant arylsulfatase A
NO347673B1 (no) *	2006-04-04	2024-02-19	Takeda Pharmaceuticals Co	En sammensetning som omfatter konsentrert polypeptide og bruk derav.
CA2790786C (en) *	2010-02-24	2019-09-24	Zymenex A/S	Process for production and purification of recombinant lysosomal alpha-mannosidase
JP6045493B2 (ja) *	2010-06-25	2016-12-14	シャイアーヒューマンジェネティックセラピーズインコーポレイテッド	アリールスルファターゼａのｃｎｓ送達の方法および組成物
JP6073783B2 (ja)	2010-06-25	2017-02-01	シャイアーヒューマンジェネティックセラピーズインコーポレイテッド	ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
CA2803166C (en) *	2010-06-25	2023-03-07	Shire Human Genetic Therapies, Inc.	Cns delivery of therapeutic agents
BR112012033214B1 (pt)	2010-06-25	2020-11-03	Shire Human Genetic Therapies, Inc.	uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente
US10336992B2 (en)	2011-07-08	2019-07-02	Shire Human Genetic Therapies, Inc.	Methods for purification of arylsulfatase A
US20140377244A1 (en)	2011-12-23	2014-12-25	Shire Human Genetic Therapies, Inc.	Stable formulations for cns delivery of arylsulfatase a
PL2920198T3 (pl) *	2012-11-13	2020-03-31	Chiesi Farmaceutici S.P.A.	Oczyszczanie rekombinowanej ludzkiej beta-galaktozydazy galaktocerebrozydowej (rhgalc)
MX2015007494A (es) *	2012-12-11	2015-12-15	Centogene Ag	Metodo para diagnosticar leucodistrofia metacromatica.
WO2014110246A1 (en)	2013-01-09	2014-07-17	Shire Human Genetic Therapies, Inc.	Methods for purification of arylsulfatase a
SG11201505926VA (en)	2013-03-15	2015-09-29	Biogen Ma Inc	Factor ix polypeptide formulations
EA202092926A3 (ru)	2014-03-24	2021-10-29	Биовератив Терапьютикс Инк.	Лиофилизированные составы, содержащие фактор ix
CN111065735B (zh) *	2017-08-31	2023-07-07	株式会社绿十字	用于纯化硫酸酯酶蛋白的方法
KR102290596B1 (ko)	2020-09-10	2021-08-19	주식회사 파이안바이오테크놀로지	분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2041280A1 (en)	1990-05-10	1991-11-11	Yosuke Sawada	Arylsulfatase
NO960163D0 (no)	1996-01-15	1996-01-15	Thomas Berg	Mutasjonsdeteksjon av bovin
ATE217799T1 (de)	1998-01-27	2002-06-15	Hemebiotech As	Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
DK2270044T3 (en) *	1998-06-09	2015-01-26	Csl Behring Ag	Liquid immunoglobulin G (IgG) product
ID27417A (id) *	1998-06-09	2001-04-05	Statens Seruminstitut	Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
US6537777B1 (en)	1998-07-27	2003-03-25	Hemebiotech A/S	Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) *	1999-05-10	1999-06-03	Csl Limited	Method of increasing protein stability by removing immunoglobulin aggregates
AU774603B2 (en)	1999-07-27	2004-07-01	Zymenex A/S	Production of rhPBGD and new therapeutic methods for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases
US6812339B1 (en) *	2000-09-08	2004-11-02	Applera Corporation	Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1409695A2 (en)	2000-11-15	2004-04-21	Genzyme Corporation	Expression system for recombinant proteins
WO2002099092A2 (en) *	2001-06-07	2002-12-12	Hemebiotech A/S	Production of recombinant human lysosomal alpha-mannosidase
WO2002098455A2 (en) *	2001-06-07	2002-12-12	Hemebiotech A/S	Production of recombinant human arylsulfatase a
WO2003002731A1 (en)	2001-06-29	2003-01-09	Hemebiotech A/S	A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD)
US7232670B2 (en) *	2001-09-28	2007-06-19	St. Jude Children's Research Hospital	Targeting proteins to cells expressing mannose receptors via expression in insect cells
WO2003057179A2 (en)	2002-01-11	2003-07-17	Biomarin Pharmaceutical, Inc.	Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7118675B2 (en) *	2002-02-04	2006-10-10	Millipore Corporation	Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de)	2004-01-29	2005-06-15	Koelbl Engineering Und Consult	Gummimehl-enthaltende Elastomerlegierungen.
NZ576986A (en) *	2004-01-30	2010-12-24	Shire Pharmaceuticals Ireland Ltd	Production and purification of recombinant arylsulfatase A
PL1740204T3 (pl)	2004-04-01	2018-08-31	Chiesi Farmaceutici S.P.A.	Lecznicze zastosowanie alfa-mannozydazy
US20060051347A1 (en) *	2004-09-09	2006-03-09	Winter Charles M	Process for concentration of antibodies and therapeutic products thereof
NO347673B1 (no) *	2006-04-04	2024-02-19	Takeda Pharmaceuticals Co	En sammensetning som omfatter konsentrert polypeptide og bruk derav.

2007
- 2007-04-04 NO NO20211305A patent/NO347673B1/no unknown
- 2007-04-04 EP EP08166902.0A patent/EP2100898B1/en active Active
- 2007-04-04 MX MX2008012748A patent/MX2008012748A/es active IP Right Grant
- 2007-04-04 EP EP13167428.5A patent/EP2631242B1/en active Active
- 2007-04-04 NZ NZ62312307A patent/NZ623123A/en unknown
- 2007-04-04 NZ NZ568728A patent/NZ568728A/en unknown
- 2007-04-04 ES ES13167428T patent/ES2928096T3/es active Active
- 2007-04-04 CA CA2632528A patent/CA2632528C/en active Active
- 2007-04-04 PL PL13167427T patent/PL2628746T3/pl unknown
- 2007-04-04 NZ NZ607595A patent/NZ607595A/en unknown
- 2007-04-04 NZ NZ571610A patent/NZ571610A/en unknown
- 2007-04-04 JP JP2009503414A patent/JP2009532394A/ja active Pending
- 2007-04-04 KR KR1020157023398A patent/KR20150103339A/ko not_active Ceased
- 2007-04-04 NZ NZ582045A patent/NZ582045A/en unknown
- 2007-04-04 BR BRPI0709737-9A patent/BRPI0709737A2/pt not_active Application Discontinuation
- 2007-04-04 EP EP07711305.8A patent/EP2004672B1/en active Active
- 2007-04-04 HU HUE13167427A patent/HUE042402T2/hu unknown
- 2007-04-04 PL PL13167428.5T patent/PL2631242T3/pl unknown
- 2007-04-04 KR KR1020087026971A patent/KR101504969B1/ko active Active
- 2007-04-04 SI SI200732097T patent/SI2628746T1/sl unknown
- 2007-04-04 ES ES13167427T patent/ES2713488T3/es active Active
- 2007-04-04 EP EP13167427.7A patent/EP2628746B1/en active Active
- 2007-04-04 NZ NZ597548A patent/NZ597548A/xx unknown
- 2007-04-04 CA CA2644642A patent/CA2644642C/en active Active
- 2007-04-04 PT PT13167427T patent/PT2628746T/pt unknown
- 2007-04-04 KR KR1020147010563A patent/KR20140057678A/ko not_active Ceased
- 2007-04-04 CN CN201510510807.4A patent/CN105233276A/zh active Pending
- 2007-04-04 ES ES08166902T patent/ES2744499T3/es active Active
- 2007-04-04 WO PCT/DK2007/000177 patent/WO2007112757A2/en not_active Ceased
- 2007-04-04 CA CA2882501A patent/CA2882501C/en active Active
- 2007-04-04 DK DK13167427.7T patent/DK2628746T3/en active
- 2007-04-04 US US12/295,848 patent/US20090246187A1/en not_active Abandoned
- 2007-04-04 AU AU2007234195A patent/AU2007234195B2/en active Active
- 2007-04-04 NZ NZ588903A patent/NZ588903A/xx unknown
- 2007-04-04 PL PL08166902T patent/PL2100898T3/pl unknown
2008
- 2008-05-30 NO NO20082510A patent/NO20082510L/no not_active Application Discontinuation
- 2008-06-19 ZA ZA2008/05346A patent/ZA200805346B/en unknown
- 2008-09-22 IL IL194267A patent/IL194267A/en active IP Right Grant
- 2008-09-26 AU AU2008229659A patent/AU2008229659B2/en active Active
- 2008-11-07 ZA ZA2008/09540A patent/ZA200809540B/en unknown
- 2008-11-12 NO NO20084776A patent/NO346368B1/no unknown
2009
- 2009-07-09 JP JP2009162789A patent/JP5384232B2/ja active Active
2011
- 2011-03-24 IL IL211905A patent/IL211905A0/en unknown
- 2011-04-26 US US13/094,321 patent/US8809055B2/en active Active
2013
- 2013-06-12 JP JP2013123735A patent/JP2013236633A/ja active Pending
- 2013-10-02 JP JP2013207384A patent/JP5878152B2/ja active Active
- 2013-10-02 JP JP2013207365A patent/JP2014058521A/ja not_active Withdrawn
2014
- 2014-07-01 US US14/321,642 patent/US20140314735A1/en not_active Abandoned
- 2014-11-30 IL IL235982A patent/IL235982A0/en unknown
2015
- 2015-09-16 IL IL241654A patent/IL241654B/en active IP Right Grant
- 2015-11-16 JP JP2015223865A patent/JP2016104000A/ja active Pending
2016
- 2016-02-11 US US15/041,841 patent/US9713634B2/en active Active
2017
- 2017-03-29 US US15/473,460 patent/US20170202927A1/en not_active Abandoned
- 2017-05-03 US US15/585,916 patent/US20180289777A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2008229659A1 (en)	2008-10-23
JP2013236633A (ja)	2013-11-28
NO20211305A1 (no)	2008-10-31
KR20150103339A (ko)	2015-09-09
PT2628746T (pt)	2019-04-23
CA2632528C (en)	2022-07-12
US20180289777A1 (en)	2018-10-11
JP2014058521A (ja)	2014-04-03
MX2008012748A (es)	2009-01-07
US8809055B2 (en)	2014-08-19
IL194267A (en)	2015-10-29
EP2631242B1 (en)	2022-08-03
CA2882501C (en)	2021-09-07
JP5878152B2 (ja)	2016-03-08
NO20084776L (no)	2008-10-31
CA2632528A1 (en)	2007-10-11
KR20090018894A (ko)	2009-02-24
IL194267A0 (en)	2011-08-01
EP2004672A2 (en)	2008-12-24
NZ582045A (en)	2011-07-29
EP2100898A1 (en)	2009-09-16
PL2628746T3 (pl)	2019-07-31
ZA200805346B (en)	2018-11-28
WO2007112757A3 (en)	2008-02-28
NZ588903A (en)	2012-08-31
NO346368B1 (no)	2022-06-27
SI2628746T1 (sl)	2019-04-30
JP2014051503A (ja)	2014-03-20
IL211905A0 (en)	2011-05-31
PL2631242T3 (pl)	2023-03-20
NZ597548A (en)	2013-08-30
ES2713488T3 (es)	2019-05-22
AU2007234195B2 (en)	2013-02-07
EP2628746A2 (en)	2013-08-21
US20090246187A1 (en)	2009-10-01
AU2007234195A1 (en)	2007-10-11
BRPI0709737A2 (pt)	2011-07-26
HUE042402T2 (hu)	2019-06-28
EP2004672B1 (en)	2015-08-19
US20140314735A1 (en)	2014-10-23
PL2100898T3 (pl)	2019-11-29
US9713634B2 (en)	2017-07-25
ZA200809540B (en)	2019-09-25
US20170202927A1 (en)	2017-07-20
WO2007112757A2 (en)	2007-10-11
CA2882501A1 (en)	2007-10-11
NZ571610A (en)	2011-07-29
DK2628746T3 (en)	2019-04-01
CA2644642A1 (en)	2007-10-11
EP2631242A2 (en)	2013-08-28
KR101504969B1 (ko)	2015-03-24
IL235982A0 (en)	2015-01-29
JP2016104000A (ja)	2016-06-09
CA2644642C (en)	2016-01-26
IL241654A0 (en)	2015-11-30
JP2009532394A (ja)	2009-09-10
AU2008229659B2 (en)	2013-01-31
EP2100898B1 (en)	2019-06-19
NZ623123A (en)	2015-04-24
KR20140057678A (ko)	2014-05-13
ES2744499T3 (es)	2020-02-25
US20120076767A1 (en)	2012-03-29
NZ568728A (en)	2011-09-30
NO20082510L (no)	2008-10-31
CN105233276A (zh)	2016-01-13
US20160193304A1 (en)	2016-07-07
NZ607595A (en)	2014-10-31
JP5384232B2 (ja)	2014-01-08
NO347673B1 (no)	2024-02-19
IL241654B (en)	2019-02-28
EP2628746B1 (en)	2019-01-09
EP2628746A3 (en)	2014-03-19
JP2009273469A (ja)	2009-11-26
EP2631242A3 (en)	2013-10-02

Publication	Publication Date	Title
ES2744499T3 (es)	2020-02-25	Un proceso para la concentración de un polipéptido
ES2981983T3 (es)	2024-10-14	Composición de hialuronidasa soluble
HK1189007B (en)	2023-03-10	A process for concentration of a polypeptide
HK1188604A (en)	2014-05-09	A process for the concentration of a polypeptide
HK1189007A (en)	2014-05-23	A process for concentration of a polypeptide
HK1188604B (en)	2019-09-27	A process for the concentration of a polypeptide
HK1219671A (en)	2017-04-13	A process for concentration of a polypeptide
HK1219671A1 (en)	2017-04-13	A process for concentration of a polypeptide
ES2824623T3 (es)	2021-05-12	Proceso para la producción y purificación de alfa-manosidasa lisosómica recombinante
ES2672646T3 (es)	2018-06-15	Uso medicinal de alfa-manosidasa